This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jung, P. Search for Related Content PubMed PubMed Citation Articles by Jung, P. Related Collections Ethical Issues Personal Experience ("Narrative Matters") Pharmaceuticals Physicians

Narrative Matters

No Free Lunch

PREFACE: It is no secret that drug companies operate in a world of high risks and potentially high gains. Recouping large investments made in new drug research and development and maximizing corporate profits depend on persuading the medical community to prescribe as much of specific medications as possible. That persuasion takes many forms, including funding research, sponsoring educational events, and providing a variety of promotional gifts to physicians. The ubiquity and expense of these efforts raise difficult ethical questions for physicians and the public. Paul Jung, an internist recently out of residency, and Howard Brody, a veteran medical educator, explore the vulnerabilities of physicians to the blandishments of drug promotion. Jung is concerned about physicians’ hunger, real and metaphorical, and Brody about a sense of entitlement that tends to drop physicians’ guard to potential intellectual compromises. Frank Davidoff, editor emeritus of the Annals of Internal Medicine, recounts his experience struggling with the conflicts of interest inherent in manuscripts submitted by authors whose research was sponsored by drug firms. Commenting on the articles from the perspective of the industry, Bert Spilker, a senior vice-president of the Pharmaceutical Research and Manufacturers of America, explains the valuable role that drug representatives can play in educating physicians about new drugs and, in turn, improving treatment for patients.

The first 100 words of the full text of this article appear below.

A few months after settling into my internship four years ago, I found a pack of M&M candies in my mailbox. Assuming that the chief residents were rewarding their charges with a little treat, I took the packet, then noticed the sticker: "Compliments of Boehringer Ingelheim Pharmaceuticals, maker of Atrovent and Combivent." The same packets sat in most of the other residents’ boxes, and empty wrappers littered the corner trash can. I immediately wrote a note to our program director, attached the M&Ms, and placed both in his in-box. His secretary could tell that I wasn’t pleased.

Every year U.S. . . . [Full Text of this Article]

Gifts And Good Food

 

Trying To Change Minds

 

Back To Square One

 

A Stopped Buck

 

Feeding The Soul

 

                      What's this?

This article has been cited by other articles:

				M. M. Khan Murky waters: the pharmaceutical industry and psychiatrists in developing countries Psychiatr. Bull., March 1, 2006; 30(3): 85 - 88. [Full Text] [PDF]

				A. C. Tsai Policies to Regulate Gifts to Physicians From Industry JAMA, October 1, 2003; 290(13): 1776 - 1776. [Full Text] [PDF]